PRESS RELEASE: Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, announced today the initiation of a U.S. Phase II study with its novel sodium channel blocker, NW-3509, in patients...
![](http://rc.feedsportal.com/r/244160279337/u/419/f/617399/c/34021/s/4bf15de3/sc/28/rc/1/rc.img)
![](http://rc.feedsportal.com/r/244160279337/u/419/f/617399/c/34021/s/4bf15de3/sc/28/rc/2/rc.img)
![](http://rc.feedsportal.com/r/244160279337/u/419/f/617399/c/34021/s/4bf15de3/sc/28/rc/3/rc.img)
![](http://da.feedsportal.com/r/244160279337/u/419/f/617399/c/34021/s/4bf15de3/sc/28/a2.img)
![](http://pi.feedsportal.com/r/244160279337/u/419/f/617399/c/34021/s/4bf15de3/sc/28/a2t.img)